FOLH1 and metastatic neoplasm: Others have demonstrated similar findings showing an improved survival in men with newly diagnosed metastatic prostate cancer depending on the year of diagnosis in a population-based setting, and, that it was possible to identify more men with low-volume metastatic disease with the use of prostate-specific membrane antigen positron emission tomography compared to conventional imaging [27,28].